<DOC>
	<DOCNO>NCT00392340</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , topotecan , vincristine , doxorubicin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well give topotecan together vincristine doxorubicin work treat young patient refractory stage 4 neuroblastoma .</brief_summary>
	<brief_title>Topotecan , Vincristine , Doxorubicin Treating Young Patients With Refractory Stage 4 Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Assess whether treatment topotecan hydrochloride , vincristine , doxorubicin hydrochloride achieve satisfactory response rate pediatric patient stage 4 neuroblastoma fail respond rapid first-line treatment . Secondary - Determine time progression patient . - Determine toxicity regimen patient . OUTLINE : This multicenter , open-label study . Patients receive topotecan hydrochloride IV 30 minute day 1-5 vincristine IV continuously doxorubicin hydrochloride IV continuously 48 hour day 5 6 . Patients also receive filgrastim ( G-CSF ) subcutaneously begin day 9 continue blood count recover . Treatment repeat every 21-28 day 2 course absence disease progression unacceptable toxicity . Patients achieve partial response ( PR ) two course treatment receive additional two course . Patients achieve complete response good PR treat accord standard therapy protocol SIOP-EUROPE- HR-NBL-1 . Patients fail achieve PR 2 course receive treatment physician 's discretion . Patients follow periodically least 3 year . PROJECTED ACCRUAL : A total 63 patient accrue study .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis stage 4 neuroblastoma Failed achieve adequate metastatic partial response firstline therapy enrol protocol SIOPEUROPEHRNBL1 PATIENT CHARACTERISTICS : Neutrophil count &gt; 1,000/mm³ Platelet count ≥ 100,000/mm³ Creatinine ≤ 1.36 mg/dL Bilirubin ≤ 2.92 mg/dL AST ALT &lt; 2.5 time upper limit normal Glomerular filtration rate ≥ 60 mL/min Normal cardiac function echocardiography No severe organ dysfunction No active hepatitis C hepatitis B virus positivity No HIV infection PRIOR CONCURRENT THERAPY : No antitumor chemotherapy within past 10 day No radiotherapy within past 30 day No investigational drug within past 30 day No prior doxorubicin hydrochloride</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
</DOC>